Moore F D, Osteen R T, Karp D D, Steele G, Wilson R E
Arch Surg. 1981 Apr;116(4):405-7. doi: 10.1001/archsurg.1981.01380160021005.
The records of 32 cancer patients who were treated with heparin sodium and warfarin sodium for thromboembolic disease were reviewed. Standard techniques for anticoagulation were neither safe nor effective. Sixteen patients experienced 21 different hemorrhagic complications. Eight patients had major hemorrhages that led to cessation of therapy or death. Six of 32 patients had pulmonary embolisms while receiving anticoagulants. It is suggested that venous interruption may be a safer and more effective method of prophylaxis against pulmonary embolism in cancer patients.
回顾了32例因血栓栓塞性疾病接受肝素钠和华法林钠治疗的癌症患者的记录。标准抗凝技术既不安全也无效。16例患者出现了21种不同的出血并发症。8例患者发生严重出血，导致治疗中断或死亡。32例患者中有6例在接受抗凝治疗时发生肺栓塞。有人认为，静脉阻断可能是预防癌症患者肺栓塞更安全、更有效的方法。
